Alembic Pharmaceuticals (NSE:APLLTD) Accounts Receivable: ₹ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:APLLTD Alembic Pharmaceuticals Ltd NSE:APLLTD
85 GF Score
Price ₹848.75
GF Value ₹1,104.09
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alembic Pharmaceuticals Accounts Receivable?

Alembic Pharmaceuticals NSE:APLLTD +2.39% 85 Accounts Receivable is ₹ Mil as of Jun. 2026. GuruFocus rates NSE:APLLTD with a GF Score™ of 85/100 and a GF Value™ of ₹1,104.09 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Alembic Pharmaceuticals's accounts receivables for the quarter that ended in Jun. 2026 was ₹ Mil.

Accounts receivable can be measured by Days Sales Outstanding. Alembic Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Alembic Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was ₹N/A.

Alembic Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Alembic Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=/21497.7*91
=0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Alembic Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Alembic Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(+0.75 * +0.5 * 0-N/A
--)/196.563124
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Alembic Pharmaceuticals Accounts Receivable Related Terms

Alembic Pharmaceuticals Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Alembic Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alembic Pharmaceuticals Accounts Receivable Chart

Alembic Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,071.30 10,464.00 10,248.40 13,997.90 14,663.00

Alembic Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 13,139.30 - 14,663.00 -
NSE:APLLTD
85GF Score
Alembic Pharmaceuticals Ltd NSE:APLLTD
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alembic Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of ₹ Mil mean?
Alembic Pharmaceuticals (NSE:APLLTD) has a Accounts Receivable of ₹ Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Alembic Pharmaceuticals and its competitors.
Is Alembic Pharmaceuticals' Accounts Receivable too high?
Alembic Pharmaceuticals' current Accounts Receivable is ₹ Mil. Overall, Alembic Pharmaceuticals has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' Accounts Receivable compare to ZTS?
Alembic Pharmaceuticals' Accounts Receivable of ₹ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Drug Manufacturers company?
A good Accounts Receivable depends on the Drug Manufacturers industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Alembic Pharmaceuticals and its competitors. Alembic Pharmaceuticals's current Accounts Receivable is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (NSE:APLLTD) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,104.09, compared to a current price of ₹848.75 — trading 23.1% below its estimated fair value. The current Accounts Receivable is ₹ Mil. Alembic Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Alembic Pharmaceuticals (NSE:APLLTD), the current Accounts Receivable is ₹ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alembic Pharmaceuticals (NSE:APLLTD) Overvalued in 2026?

Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued. The current stock price of ₹848.75 is trading 23.1% below its estimated GF Value™ of ₹1,104.09. GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:APLLTD:

  • Accounts Receivable: ₹ Mil
  • GF Value™: ₹1,104.09 vs. price of ₹848.75 (23.1% below fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the NSE:APLLTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alembic Pharmaceuticals Business Description

Other Exchanges 533573:India
Address Alembic Road, Vadodara, GJ, IND, 390 003
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
85GF Score

Get the complete analysis for NSE:APLLTD

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹848.75
Price
₹1,104.09
GF Value